With its liquid biopsy approval, Foundation Medicine takes on Guardant | Evaluate
![Foundation Medicine review - 7 facts you should know [DECEMBER 2021]](https://nebula.org/blog/wp-content/uploads/2021/12/FoundationOne-CDx-testing-kit.png "Foundation Medicine review - 7 facts you should know [DECEMBER 2021]")
Foundation Medicine review - 7 facts you should know [DECEMBER 2021]
FoundationOne Liquid CDx
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin | PLOS ONE
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications
First Comprehensive Next-gen Sequencing based Pan-Tumor Liquid Biopsy Test Approved - Onco'Zine
Foundation Medicine launches liquid biopsy test - MedCity News
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks
Foundation Medicine Announces Commercial Launch of Solid Tumor Liquid Biopsy
Foundation Medicine receives FDA approval for pan-tumour biopsy test
Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test - MedCity News
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Business Wire
FoundationOne Liquid
FoundationOne Liquid CDx
Foundation Medicine acquires liquid biopsy developer Lexent Bio | Fierce Biotech
Multi-gene Testing (NGS) for PIK3CA Mutations
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Gustave Roussy
FoundationOne Liquid CDx
